-
First trimester prediction of HELLP syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenat Diagn 2016;36:29-33. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2016;215:87.e1-87.e17. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH.
Am J Obstet Gynecol 2016;214:619.e1-619.e17. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2016;214:103.e1-103.e12 . pdf -
Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-73. -
The use of ultrasound and other markers for early detection of preeclampsia.
O'Gorman N, Nicolaides KH, Poon LC.
Womens Health (Lond) 2016;12:199-207. pdf -
Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;35:249-57. pdf -
Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;36:106-16.. pdf -
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Bujold E, Roberge S, Nicolaides KH.
Prenat Diagn 2014;34:642-8. pdf -
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Comparison of two different sites of measurement for transabdominal uterine artery Doppler velocimetry at 11-13 weeks.
Lefebvre J, Demers S, Bujold E, Nicolaides KH, Girard M, Brassard N, Audibert F.
Ultrasound Obstet Gynecol 2012;40:288-92. -
Association of placental volume measured by MRI and birth weight percentile.
Derwig IE, Akolekar R, Zelaya FO, Gowland PA, Barker GJ, Nicolaides KH.
J Magn Reson Imaging 2011;34:1125-30. -
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenat Diagn 2009;29:553-9. -
Effect of parity on maternal cardiac function during the first trimester of pregnancy.
Turan OM, De Paco C, Kametas N, Khaw A, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:849-54. -
First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:15-9. -
Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:871-6. -
First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstet Gynecol 2008;112:1082-90. -
Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy.
Makrydimas G, Sotiriadis A, Savvidou MD, Spencer K, Nicolaides KH.
Prenat Diagn 2008;28:175-9.